Adaptive Biotechnologies ADPT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's operating cash flow?
- Adaptive Biotechnologies (ADPT) reported operating cash flow of -$9.54M in Q1 2026.
- How has Adaptive Biotechnologies's operating cash flow changed year-over-year?
- Adaptive Biotechnologies's operating cash flow increased by 66.5% year-over-year, from -$28.48M to -$9.54M.
- What is the long-term trend for Adaptive Biotechnologies's operating cash flow?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's operating cash flow has grown at a -29.3% compound annual growth rate (CAGR), from -$192.73M to -$48.04M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.